Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label adverse events. Show all posts
Showing posts with label adverse events. Show all posts
Saturday, May 26, 2012

Is Renal Thrombotic Angiopathy a Potential Problem in the Chronic Treatment of Ovarian Cancer?

›
UNC Kidney Center:  thrombotic microangiopathy                            ~~~~~~~~~~~~~~~~~~ Is Renal Thrombotic Angiopathy a Potential ...
Thursday, May 17, 2012

paywalled - Gynecologic Oncology - Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer

›
ScienceDirect.com - Gynecologic Oncology - Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer O...
Wednesday, May 16, 2012

Healthnewsreviews blog: The marketing of anemia drugs - a story we shouldn't forget (including comments)

›
The marketing of anemia drugs - a story we shouldn't forget  "In an opinion piece on TheScientist.com, Daniel W. Coyne writes , ...

FAQ: Adverse Events(search by drug name)

›
FAQ: Adverse Events About Us Adverse Events, Inc. (AEI) is a provider of up-to-the-minute, critical, potentially life-saving inform...
Tuesday, May 01, 2012

paywalled: Evaluation of prevalent and incident ovarian cancer co-morbidity : British Journal of Cancer

›
Access : Evaluation of prevalent and incident ovarian cancer co-morbidity : British Journal of Cancer British Journal of Cancer , (1 Ma...

press release: Risks of mixing drugs and herbal supplements: What doctors and patients need to know

›
Risks of mixing drugs and herbal supplements: What doctors and patients need to know
Wednesday, April 25, 2012

open access: Oxaliplatin-related thrombocytopenia

›
Oxaliplatin-related thrombocytopenia Abstract/Full Text: Oxaliplatin is a third generation platinum compound that inhibits DNA synthe...
Wednesday, April 18, 2012

Potentially Dangerous Complementary and Alternative Medicine (CAM) Use by Ovarian Cancer Patients | Abstract

›
Potentially Dangerous Complementary and Alternative Medicine (CAM) Use by Ovarian Cancer Patients Abstract Objective:   The use of...
Saturday, April 07, 2012

abstract - Gynecologic Oncology - Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer

›
Gynecologic Oncology - Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after ini...
Friday, April 06, 2012

abstract: Incontinence after colonoscopy - an unrecognized and preventable problem. A cross-sectional study from the Gastronet quality assurance program

›
 Abstract " Female patients had a higher risk of incontinence than men." Background:   Colonoscopy requires insufflation of ...
Thursday, April 05, 2012

abstract: Assessing residents' disclosure of adverse events: traditional objective structured clinical examinations versus mixed reality.

›
Assessing residents' disclosure of adv... [J Obstet Gynaecol Can. 2012] - PubMed - NCBI J Obstet Gynaecol Can. 2012 Apr;34(4):367-7...
Sunday, April 01, 2012

AACR: Selumetinib Controlled Recurrent Low-grade Serous Ovarian Cancer

›
Selumetinib Controlled Recurrent Low-grade Serous Ovarian Cancer : Selumetinib controlled the disease in 81 percent of patients. ...
Wednesday, March 21, 2012

abstract: Does long-term treatment with Doxil(®) predispose patients to oral cancer?

›
Does long-term treatment with Doxil(®) predispose patients to oral cancer? Abstract We present a possible adverse reaction related t...
Tuesday, March 20, 2012

abstract: Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery - Variability of Poly (ADP-Ribose) Polymerase Activity.

›
Wiki:  Poly ADP ribose polymerase: Poly (ADP-ribose) polymerase ( PARP ) is a family of proteins involved in a number of cellular proce...
Friday, March 16, 2012

Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions - PRNewswire

›
Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions -- WASHINGTON, March 16, 2012 /PRNewswire/ --
Thursday, March 15, 2012

abstract: Phase 1 Dose-Escalation Study of Aflibercept Plus Docetaxel

›
Phase 1 Dose-Escalation Study of Aflibercept Plus Docetaxel : Purpose: This phase I study cohort investigated aflibercept in combination...
Sunday, March 11, 2012

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

›
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal...

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

›
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites Objective  The reco...
Monday, January 30, 2012

links to article/commentary/blogger's notes: Intravenous Aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study : The Lancet Oncology

›
Blogger's Note :  reposted from Jan 20th due to Lancet Editorial and reference - paper is open accdess pay specific attentio...
Sunday, January 29, 2012

open access: Ports and complications for intraperitoneal chemotherapy delivery (ovarian cancer)

›
"Intraperitoneal access ports are essential to the delivery of chemotherapy agents into the peritoneal cavity of women with ovarian c...